Alzheimer’s Disease

Why Do So Many Alzheimer’s Drugs Fail in Clinical Trials?

Semagacestat, tramiprosate, tarenflurbil, latrepirdine: These names may not mean a lot to you, but all four of them were high-profile would-be Alzheimer’s drugs that — in the last two to three years — have failed the last phase of clinical trials. They made it through the safety stages okay. They just didn’t work well enough; they …

What does head size have to do with Alzheimer’s?

According to a new study published in the July 13 issue of the journal Neurology, Alzheimer’s patients with larger heads may experience a slower progression of cognitive decline symptoms, possibly because they have more of what researchers call “brain reserve” — or the ability to adjust to changes within the brain. The theory is based

Active youth linked to lower risk for cognitive decline

A new study analyzing physical activity at different phases of life for more than 9,000 elderly women finds that routine exercise at any age was associated with a reduced risk for cognitive decline or dementia, but that regular physical activity during teenage years was most strongly linked to a lower risk for mental deterioration later

A link between belly fat and dementia risk

Having excess belly fat in middle-age may increase the risk for dementia later in life, according to results of a new study published this week in the Annals of Neurology. In an analysis of 733 middle-aged men and women, researchers at the Boston University School of Medicine found that not only was higher body mass index (BMI)

Spouses of dementia patients at higher risk themselves

Compared with other aging married individuals whose husbands or wives do not suffer from dementia, those whose spouses are diagnosed with the condition are six times more likely to develop dementia themselves, according to new research published today in the Journal of the American Geriatrics Society. Researchers suggest that the stress

Potential Alzheimer’s drug fails clinical trial

A drug that held hope for many Alzheimer’s patients and their loved ones failed a late-stage clinical trial, proving negligible benefits over placebo, the New York Times reports. The drug, called Dimebon (latrepirdine), was being developed by pharmaceutical giant Pfizer together with a small new company, Medivation, but failed to meet

  1. 1
  2. ...
  3. 4
  4. 5
  5. 6
  6. 7
  7. Next